Figure 2
From: TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial
Image analysis of TLE3 staining and outcome by treatment arm. (A) Recurrence-free survival by Image analysis of TLE3: Status stratified by allocation to EC/T or CEF: TLE− CEF=patients with <30% TLE3 tumour-positive cells allocated to CEF arm. TLE3+ CEF=patients with ⩾30% TLE3 tumour-positive cells allocated to CEF arm. TLE− EC/T=patients with <30% TLE3 tumour-positive cells allocated to EC/T arm. TLE3+ EC/T=patients with ⩾30% TLE3 tumour-positive cells allocated to EC/T arm. (B) Recurrence-free survival for TLE3-positive cases by image analysis of TLE3: Status stratified by allocation to EC/T or CEF: CEF=patients allocated to CEF arm. EC/T=patients allocated to EC/T arm. (C) Recurrence-free survival for TLE3 negative cases by image analysis TLE3: Status stratified by allocation to EC/T or CEF: CEF=patients allocated to CEF arm. EC/T=patients allocated to EC/T arm.
